Significant Declines in Juvenile-onset Recurrent Respiratory Papillomatosis Following Human Papillomavirus (HPV) Vaccine Introduction in the United States
Open Access
- 18 February 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (5), 885-890
- https://doi.org/10.1093/cid/ciab171
Abstract
Juvenile-onset recurrent respiratory papillomatosis (JORRP) is a rare and serious disease caused by human papillomavirus (HPV) presumably acquired during vaginal delivery. HPV vaccination of females through age 26 years, recommended in the United States since 2006, can prevent HPV transmission. We assessed trends in JORRP cases before and after HPV vaccine introduction in the United States. Case-patients were identified from 26 pediatric otolaryngology centers in 23 U.S. states. Demographics and clinical history were abstracted from medical records. Case-patients were grouped by year of birth, and birth-cohort incidences were calculated using number of births from either national or state-level natality data from the 23 states. We calculated incidence rate ratios (IRR) and 95% confidence intervals (CI) in 2-year intervals. We identified 576 U.S. JORRP case-patients born in 2004–2013. Median age at diagnosis was 3.4 years (interquartile range: 1.9, 5.5). Number of identified JORRP case-patients declined from a baseline of 165 born in 2004–2005 to 36 born in 2012–2013. Incidence of JORRP per 100 000 births using national data declined from 2.0 cases in 2004–2005 to 0.5 cases in 2012–2013 (IRR = 0.2, 95% CI = .1–.4); incidence using state-level data declined from 2.9 cases in 2004–2005 to 0.7 cases in 2012–2013 (IRR = 0.2, 95% CI = .1–.4). Over a decade, numbers of JORRP case-patients and incidences declined significantly. Incidences calculated using national denominator data are likely underestimates; those calculated using state-level denominator data could be overestimates. These declines are most likely due to HPV vaccination. Increasing vaccination uptake could lead to elimination of this HPV-related disease.Funding Information
- Centers for Disease Control and Prevention
This publication has 34 references indexed in Scilit:
- Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010The Journal of Infectious Diseases, 2013
- Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United StatesVaccine, 2012
- Clinical features, health‐related quality of life, and adult voice in juvenile‐onset recurrent respiratory papillomatosisThe Laryngoscope, 2011
- Epidemiology of recurrent respiratory papillomatosisAPMIS, 2010
- The epidemiology of juvenile onset recurrent respiratory papillomatosis derived from a population level national databaseThe Laryngoscope, 2010
- Predictors of Remission in Juvenile-Onset Recurrent Respiratory PapillomatosisJAMA Otolaryngology–Head & Neck Surgery, 2003
- National Registry for Juvenile-Onset Recurrent Respiratory PapillomatosisJAMA Otolaryngology–Head & Neck Surgery, 2003
- Incidence and Prevalence of Recurrent Respiratory Papillomatosis among Children in Atlanta and SeattleClinical Infectious Diseases, 2000
- Initial Results From the National Registry for Juvenile-Onset Recurrent Respiratory PapillomatosisJAMA Otolaryngology–Head & Neck Surgery, 1999
- Task Force on Recurrent Respiratory Papillomas: A Preliminary ReportJAMA Otolaryngology–Head & Neck Surgery, 1995